Our mission is to develop novel drugs, such as gemcabene, to treat the large, growing unmet need of dyslipidemia patients who are unable to reach optimal LDL cholesterol or triglyceride levels with statin or other therapies.

About Gemphire

Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a clinical-stage biopharmaceutical company that is developing and commercializing therapies to help patients with cardiometabolic disorders, including dyslipidemia and NASH. We are focused on providing new treatment options for cardiometabolic diseases through our complementary, convenient, cost-effective product candidate, gemcabene (CI-1027 licensed from Pfizer in 2011), as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. Gemcabene’s lack of drug-drug interactions with highest dose of statins such as Lipitor offer a first-in-class, once-daily oral drug candidate for additional LDL-C, triglycerides (fat), and inflammation lowering.